News » Dispensary guidance news » AZ to lose patent protection for dapagliflozin
July 18th 2025
Dispensing practices are advised of reports that dapagliflozin (Forxiga) will lose patent protection – paving the way for low margin generic versions - following an unsuccessful legal bid.
The patent was cancelled in the UK Court of Appeal following a dispute between AstraZeneca and generics manufacturers Viatris, Teva and Glenmark.
According to patent information service JUVE, AstraZeneca will appeal to the Supreme Court.
At issue is AstraZeneca’s EP 1 506 211, which expired on 14 May 2023. The company is also the proprietor of UK SPCs SPC/GB13/021 and SPC/GB14/050 based on the patent, which expire on 13 and 14 May 2028.
